These results indicate that tumor-specific CD8+ T cells and NK cells play a crucial role in the observed therapeutic immunity induced by DC vaccines pulsed with CMQ-treated TCLs against B16 melanoma, whereas CD4+ T cells are only partially involved in the antitumor activity. Here, CD4 is linked to melanoma.